Smith & Nephew ANNuAl report 2013 94 FiNANCiAl StAtemeNtS Group income statement Year ended Year ended Year ended 31 December 31 December 31 December 2012 2011 2013 Restated i Restated i Notes $ million $ million $ million Revenue 2 4,351 4,137 4,270 Cost of goods sold 1,100 1,070 1,140 Gross profit 3,251 3,067 3,130 Selling, general and administrative expenses 3 2,210 2,050 2,101 Research and development expenses 3 231 171 167 Operating profit 2 & 3 810 846 862 Interest receivable 4 14 11 4 Interest payable 4 10 9 12 Other finance costs 4 11 11 13 Share of results of associates 11 1 4 Profit on disposal of net assets held for sale 21 251 Profit before taxation 802 1,092 841 Taxation 5 246 371 266 Attributable profit for the year ii 556 721 575 Earnings per ordinary share ii 6 Basic 61.7 80.4 64.5 Diluted 61.4 80.0 64.2 Group statement of comprehensive income Year ended Year ended Year ended 31 December 31 December 31 December 2012 2011 2013 Restated i Restated i Notes $ million $ million $ million Attributable profit for the year ii 556 721 575 Other comprehensive income: Items that will not be reclassified to income statement Actuarial gains losses on retirement benefit obligations 18 12 5 63 Taxation on other comprehensive income 5 16 20 24 Total items that will not be reclassified to income statement 4 15 39 Items that may be reclassified subsequently to income statement Cash flow hedges interest rate swaps losses arising in the year 1 losses transferred to income statement for the year 1 Cash flow hedges forward foreign exchange contracts gains losses arising in the year 8 1 1 gains losses transferred to inventories for the year 3 6 13 Exchange differences on translation of foreign operations 6 36 32 Exchange on borrowings classified as net investment hedges 1 4 Total items that may be reclassified subsequently to income statement 1 30 22 Other comprehensive expense income for the year, net of taxation 5 45 61 Total comprehensive income for the year ii 551 766 514 i Restated for the adoption of the revised IAS 19 Employee Benefits standard, see Note 1. ii Attributable to equity holders of the Company and wholly derived from continuing operations.
The Notes on pages 101 to 149 are an integral part of these accounts.
Group StrAteGiC report CorporAte GoverNANCe FiNANCiAl StAtemeNtS AND other iNFormAtioN Smith & Nephew ANNuAl report 2013 FiNANCiAl StAtemeNtS 95 Commentary on the Group income statement and Group statement of comprehensive income Revenue Operating profit Group revenue increased by $214m 5% on a reported basis, from Operating profit decreased by $36m to $810m from $846m in 2012.
The underlying increase is 4% This comprised a decrease of $12m in Advanced Surgical Devices after adjusting for the net impact of 2% on the Healthpoint and a decrease of $24m in Advanced Wound Management.
acquisition and Clinical Therapies disposal and 1% attributable The movement in Advanced Surgical Devices is attributable to the to the unfavourable impact of currency movements.
continuing pressure on margins and its investment in the Emerging & International Markets.
Advanced Wound Management has Cost of goods sold continued to invest in new products and new geographic markets throughout the year.
Cost of goods sold increased by $30m 3% on a reported basis from $1,070m in 2012 to $1,100m in 2013.
The underlying movement is 2% after adjusting for the net impact of 2% on the Healthpoint Net interest receivable payable acquisition and Clinical Therapies disposal and 1% attributable to the Net interest receivable increased, by $2m, from net $2m receivable favourable impact of currency movements.
The movement in in 2012 to a net receivable of $4m in 2013.
This increase is underlying costs of goods sold of 2% is largely attributable to the principally a consequence of the interest receivable on the Bioventus increase in underlying trading.
LLC Bioventus loan note issued following the disposal of the During 2013, $12m of restructuring and rationalisation expenses Clinical Therapies business which has been in place for a full year 2012 - $3m and $5m of acquisition related costs 2012 - $nil were in 2013 compared to eight months in 2012. charged to cost of goods sold.
Other finance costs Selling, general and administrative expenses Other finance costs in 2013 remained at $11m and principally relate Selling, general and administrative expenses increased by $160m to costs associated with the Groups retirement benefit schemes.
The underlying movement is 6% after adjusting for the net impact of Taxation 3% on the Healthpoint acquisition and Clinical Therapies disposal The taxation charge decreased, by $125m, to $246m from $371m and 1% attributable to the favourable impact of currency movements.
The rate of tax was 30.5%, compared with 33.7% in 2012.
The underlying increase of 6% is due to the continuing investment in After adjusting for specific transactions that management considers Emerging & International Markets, promotion of new products in affect the Groups short-term profitability profit on disposal of the ASD and AWM and the underlying increase in trading.
Clinical Therapies business, restructuring and rationalisation In 2013, administrative expenses included $64m of amortisation of expenses, amortisation of acquisition intangibles and acquisitionother intangible assets 2012 $51m, $46m of restructuring and related costs the tax rate was 29.2% 2012 29.9%.
rationalisation expenses 2012 $62m, an amount of $88m relating to amortisation of acquisition intangibles 2012 $43m and $26m of acquisition related costs 2012 $11m.
Research and development expenses Research and development expenditure as a percentage of revenue increased by 1.2% to 5.3% in 2013 2012 4.1%.
Actual expenditure was $231m in 2013 compared to $171m in 2012.
The Group continues to invest in innovative technologies and products to differentiate it from competitors.
It also continues to invest in HP802- 247, currently in Phase III trials, which was acquired as part of the Healthpoint acquisition in December 2012.
The financial commentary on this page forms part of the business review and is unaudited.
See pages 164 to 167 for commentary on the 2012 financial year.
